Do you want to read an article? Please log in or register.
TROPION-Lung01: Dato-DXd benefits patients with advanced non-squamous NSCLC with or without brain metastases
Lung, Respiratory and Thoracic Cancer
ESMO 2024
Related content
ESMO 2024
Breast Cancer
DESTINY-Breast12: T-DXd proved effective in patients with HER2-positive metastatic breast cancer with or without brain metastases
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Quantitative Continuous Scoring of TROP2 Normalized Membrane Ratio Predicts Clinical Outcomes in Patients With NSCLC
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
J Clin Oncol
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J, TROPION-Lung01 Trial Investigators
doi: 10.1200/JCO-24-01544
Lung, Respiratory and Thoracic Cancer
Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis
Lung Cancer
Aptekar J, Jain R, Korytowsky B, Shafquat A, Hendershot J, Talwai A, Itzkovich Y, Padda SK
doi: 10.1016/j.lungcan.2024.107854
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Eur J Cancer
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, Vita E, Gelsomino F, De Giglio A, Gelibter A, Siringo M, Mazzoni F, Caliman E, Genova C, Bertolini F, Guaitoli G, Passiglia F, Delcuratolo MD, Montrone M, Cerea G, Pasello G, Roca E, Belluomini L, Cecere FL, Guida A, Manzo A, Adamo V, Rastelli F, Bulotta A, Citarella F, Toschi L, Zoratto F, Cortinovis DL, Berardi R, Follador A, Carta A, Camerini A, Salerno F, Silva RR, Baldini E, Cortellini A, Brighenti M, Santoni M, Malorgio F, Caminiti C, Tiseo M
doi: 10.1016/j.ejca.2024.114006
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer
Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M, East Japan Chesters Group
doi: 10.1016/j.lungcan.2024.107540
Lung, Respiratory and Thoracic Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)
Lung Cancer
Johnson M, Younan D, Kent ST, Mesa-Frias M, Alan Brookhart M, Balasubramanian A, Spira A
doi: 10.1016/j.lungcan.2024.107960